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Abstract
Background: After long term disease free follow up (FUp) patients reconsider quality of life
(QOL) outcomes. Aim of this study is assess QoL in prostate cancer patients who are disease-free
at least 5 years after radical prostatectomy (RP).
Methods: 367 patients treated with RP for clinically localized pCa, without biochemical failure
(PSA ≤ 0.2 ng/mL) at the follow up ≥ 5 years were recruited.
Urinary (UF) and Sexual Function (SF), Urinary (UB) and Sexual Bother (SB) were assessed by using
UCLA-PCI questionnaire. UF, UB, SF and SB were analyzed according to: treatment timing (age at
time of RP, FUp duration, age at time of FUp), tumor characteristics (preoperative PSA, TNM stage,
pathological Gleason score), nerve sparing (NS) procedure, and hormonal treatment (HT).
We calculated the differences between 93 NS-RP without HT (group A) and 274 non-NS-RP or
NS-RP with HT (group B). We evaluated the correlation between function and bother in group A
according to follow-up duration.
Results: Time since prostatectomy had a negative effect on SF and a positive effect SB (both p <
0.001). Elderly men at follow up experienced worse UF and SF (p = 0.02 and p < 0.001) and better
SB (p < 0.001).
Higher stage PCa negatively affected UB, SF, and SB (all: p ≤ 0.05). NS was associated with better
UB, SF and SB (all: p ≤ 0.05); conversely, HT was associated with worse UF, SF and SB (all: p ≤ 0.05).
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Health and Quality of Life Outcomes 2009, 7:94 http://www.hqlo.com/content/7/1/94More than 8 years after prostatectomy SF of group A and B were similar. Group A subjects (NS-
RP without HT) demonstrated worsening SF, but improved SB, suggesting dissociation of the
correlation between SF and SB over time.
Conclusion: Older age at follow up and higher pathological stage were associated with worse
QoL outcomes after RP. The direct correlation between UF and age at follow up, with no
correlation between UF and age at time of RP suggests that other issues (i.e: vascular or neurogenic
disorders), subsequent to RP, are determinant on urinary incontinence. After NS-RP without HT
the correlation between SF and SB is maintained for 7 years, after which function and bother appear
to have divergent trajectories.
Background
Prostate cancer and its treatments are costly and signifi-
cantly impact quantity and quality of life; moreover, most
prostate cancer survivors receive a significant portion of
their care as outpatients [1]. Radical prostatectomy, in
addition to represent one of the best approach for long
term cancer control in clinically localized PCa [2], has a
remarkable impact on patient's quality of life (QoL).
Although the primary goal of any innovative treatment for
prostate cancer is to maximize life expectancy, both
patients and clinicians are currently devoting more atten-
tion to the impact of current therapies on QoL outcomes
[3]. For many patients, the QoL impact of treatment deter-
mines the therapy selection among the currently available
approaches [4]. Toward that end, several new surgical
developments have attempted to maximize QoL after
prostatectomy [5].
Urinary incontinence and erectile dysfunction are the
most prominent side effects of radical prostatectomy [6].
The severity of patient-reported symptoms can be very dif-
ferent from symptom-related bother. Several items can
affect both symptoms and bother in different ways. Uri-
nary and sexual symptoms and bother are usually depend-
ent on age at the time of surgery [7]. In addition, after
long-term disease-free follow-up, patients have a propen-
sity to reconsider their QoL status [8], even if aging can
worsen overall patient health. Moreover, patients with
high-risk PCa may better tolerate long term adverse events
than those with low-risk PCa. Finally, a bilateral nerve-
sparing approach, as well as the requirement for postop-
erative hormone treatment, can be major determinants of
sexual QoL after prostatectomy [9].
The aims of the present study are: 1) to assess QoL out-
comes in prostate cancer survivors who are disease-free at
least 5 years after radical prostatectomy, 2) to identify the
primary determinants of long-term QoL, and 3) to evalu-
ate the impact of nerve-sparing surgery without hormone
therapy on long-term urinary and sexual outcomes.
Methods
Study population
Our study population was composed of patients who had
undergone radical retropubic prostatectomy (RP) for PCa
in 2 centers of excellence between 1995-2002. Patients
included underwent RP with either a bilateral nerve (NS)
or non-nerve sparing (non-NS) approach as primary ther-
apy for clinically localized prostate cancer (cT1-cT2, N0,
M0), maintained a postoperative PSA ≤ 0.2 ng/mL with fol-
low-up of at least 5 years, and completed our study ques-
tionnaire. The follow-up schedule included serum PSA
assay every 3 months for the first year, then every 6
months for the following two years and yearly thereafter.
Biochemical relapse was defined as evidence of PSA > 0.2
ng/mL at two consecutive measurements.
Informed consent was obtained from all subjects. This
trial was carried out in accordance with the ethic princi-
ples of the Helsinki declaration (1996) and good clinical
practice issues (1997) and was reviewed and approved by
both the local ethics committee.
We excluded those with preoperative urinary inconti-
nence (assessed by medical history, at time of hospitaliza-
tion), those who received neoadjuvant or adjuvant
radiotherapy, those with incomplete pre or postoperative
data, those who underwent unilateral NS-RP or in whom
the NS status could not be determined, with an inability
to complete the questionnaire, and refusal to participate.
Furthermore, patients without a partner or without a sex-
ual activity in the year before prostatectomy were
excluded from the study, to improve the assessment of the
sexual bother outcomes.
Patients with preoperative PSA ≤ 10 ng/ml, biopsy Gleason
score ≤ 7, age at diagnosis ≤ 70 years, and preoperative IIEF
score ≥ 20 were selected for NS-RP. All patients treated
with a NS-RP used several ED treatments (including vac-
uum device, penile injections, and recently PDE-5 inhibi-
tors), used subsequently or in combined therapies, with
the aim to preserve or recover their sexual function.Page 2 of 8
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Health and Quality of Life Outcomes 2009, 7:94 http://www.hqlo.com/content/7/1/94All RP specimens were fixed in formalin, coated with
India ink, weighed, and serially sectioned, staged, and
graded according to the 2002 American Joint Committee
on Cancer (AJCC) staging system.
Follow-up included serum PSA every 3 months for the
first two years, every 6 months for the following three
years, and yearly thereafter. Biochemical relapse was
defined as PSA > 0.2 ng/ml on 2 consecutive measure-
ments. Patients with biochemical recurrence were treated
with adjuvant hormonal therapy (LHRH analog with or
without anti-androgen) at time of biochemical relapse.
HRQOL measures
We used the validated Italian version of the UCLA Prostate
Cancer Index (PCI) [10], that assesses urinary continence
and sexual function and their impact on related bother.
We directly interviewed patients face to face, and they
completed the questionnaire in a self reported fashion.
This questionnaire allows evaluation of the detailed
symptoms as well as their corresponding bother. For this
analysis, we focused on subject urinary and sexual func-
tion (UF and SF) and urinary and sexual bother (UB and
SB). Responses were scored from 0 to 100, with a higher
score indicating better QoL.
Statistical analysis
We evaluated in the statistical analysis the correlation
between function and bother and subject demographic
and clinical characteristics with Pearson correlation coef-
ficients. Variables that were significant on univariate anal-
ysis were incorporated into a linear regression model
(forward, stepwise variable entry) for multivariate analy-
sis of factors influencing the items to evaluate postopera-
tive urinary and sexual QoL over time. SF and SB
outcomes were evaluated for all patients (n = 367) and for
those who underwent NS-RP without HT (Group A, n =
93). Differences at 4 follow-up times (5, 6-7, 8-9, and ≥ 10
years) in UF, UB, SF and SB scores between Group A sub-
jects and the other 274 subjects treated with non-NS-RP or
NS-RP and subsequent HT (Group B) were assessed by
using unpaired samples t-tests. Finally, we calculated the
correlation between UF and UB and between SF and SB of
subjects in Group A at the above mentioned 4 different
follow-up intervals with Pearson correlation coefficients.
Results
Patient characteristics
We overall collected 367 questionnaires: 307 men pre-
sented a follow up time > 5 years (mean 95.5 months, r:
61-156), while for the remaining 60 men follow up time
was 5 years (60 months). Clinical presentation, patholog-
ical findings and follow up time of the whole population
and both subgroups of 5 years amd more than 5 years fol-
low up are listed in table 1. Mean age at RP was 64.8 years
(median 66, range 47-77) and mean follow-up time was
89.7 months (median 84, range 60-156). Sixty subjects
(16.3%) had follow-up of 5 years, 146 subjects (39.8%)
Table 1: Clinical presentation and pathological findings of the 367 patients
Overall F.up 5 yy F.up > 5 yy
N° of patients 367 60 307
Mean age (years), (median, range) 64.8 (66, 47-77) 64.1 (65, 49-74) 64.9 (66, 47-77)
Mean follow up (months), (median, range) 89.7 (84, 60-156) 60 95.5 (87, 61-156)
Follow up time: (years) n (%)
5 60 (16.3)
6-7 146 (39.8)
8-9 81 (22.1)
> 10 80 (21.8)
Pre-operative PSA (ng/ml)
mean (median, range)
14.6 (10.2, 0.8-87) 12.8 (9, 3.9 - 63) 15 (10.6, 0.8-87)
Pre-operative PSA (ng/ml) n (%) n (%) n (%)
<10 165 (45.0) 34 (56.6) 131 (42.7)
10-20 134 (36.5) 17 (28.3) 121 (39.4)
>20 68 (18.5) 9 (15.1) 55 (17.9)
Specimen Gleason Score n (%) N (%) n (%)
2-6 154 (42.0) 31 (51.7) 123 (40.1)
7 146 (39.8) 19 (31.7) 127 (41.3)
8-10 67 (18.2) 10 (16.6) 57 (18.6)
Pathological stage (TNM 1997) n (%) n (%) n (%)
T2 222 (60.5) 40 (66.7) 182 (59.3)
T3a 77 (21.0) 13 (21.6) 64 (20.8)
T3b 59 (16.1) 6 (10) 53 (17.3)
T4 9 (2.4) 1 (1.7) 8 (2.6)
Nerve sparing n (%) n (%) n (%)
125 24 (19.2) 101 (80.8)Page 3 of 8
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years follow-up, and 80 subjects (21.8%) had follow-up
beyond 10 years. Of the 367 subjects, mean preoperative
PSA was 14.6 ng/ml (median 10.2, range 0.8-87): 165
(45.0%) had a PSA <10, 134 (36.5%) had a PSA between
10-20, and 68 (18.5%) had a PSA > 20 ng/ml. Pathologic
stage was T2 in 222 subjects (60.5%), pT3a in 77 subjects
(21.0%), pT3b in 59 subjects (16.1%) and pT4 in 9 sub-
jects (2.4%). Median pathological Gleason score was 7: ≤ 6
in 154 subjects (42.0%), 7 in 146 subjects (39.8%), and
8-10 in 67 subjects (18.2%).
NS-RP was performed in 125 subject (34.1%): 24/60
(40%) patients with a follow up time of 5 years, and 101/
307 (33%) with a follow up time >5 years (see table 1),
The remaining 242 subjects (65.9%) underwent non-NS-
RP. Only recently (in the last 5 years) we used structured
procedures, with inclusion/exclusion criteria and sched-
uled treatment protocols either of profilaxis and treat-
ment of post prostatectomy ED. All patients with a follow
up time > 5 years did not undergo a structured rehabilita-
tion protocol for ED: the starting timing of drugs admin-
istration was not the same, and in many cases men started
ED treatment several months after surgery. Furthermore
the treatment of ED was outlined with different devices
(PDE5, PgE, vacuum), used subsequently or in combined
therapies. On the contrary, the remaining 24 patients with
a follow up time of 5 years (19.2%) undergone a struc-
tured profilaxis for postprostatectomy ED [11]: at follow
up time 10 patients were using PDE5-i, 9 PDE5-i plus
PGE, 1 patient needed the use of a vacuum device and 4
patients did not use any aids at all. For the heterogeneous
data from patients with follow up >5 years and the small
population of men with 5 years follow up we avoided the
stratified analyses according to the use of erectile aids.
Seventy-six subjects (20.7%) received adjuvant HT. Over-
all, 93 patients (25.3%, Group A) treated with NS-RP did
not require HT, while 274 (74.7%, Group B) underwent
either non-NS-RP (242 patients, 88.3%) or NS followed
by HT (32 patients, 11.7%).
Univariate analysis
On univariate analysis (Table 2), urinary function was
worse in older subjects, with adverse tumor characteristics
and hormone treatment likewise correlated with worse
continence. Subjects with unfavorable tumor characteris-
tics and under HT also reported worse UB scores, while
those treated with NS-RP endorsed better UB compared
with those undergoing non-NS surgery.
Treatment timing, tumor characteristics, and HT were all
negatively correlated with SF on univariate analysis, while
NS-RP was positively correlated with SF. Those with
longer follow-up, older age at follow-up, and those
treated with NS-RP had less sexual bother. Subject with
higher pathological stage and those who received HT had
worse SB.
Multivariate analysis
Multivariate analysis (Table 3) showed a significant posi-
tive correlation between follow-up duration and SB and
an inverse correlation between age at follow-up and UF.
Moreover, pathological stage negatively affected UB, SF,
and SB. Multivariate analysis confirmed the positive effect
of NS on UB and SB and corroborated the negative effect
of HT on UF.
Sexual function and sexual bother after NS-RP without HT
Concerning sexual function and bother after NS-RP with-
out hormonal treatment, sexual bother was not influ-
Table 2: Univariate analysis of the whole study sample with Pearson correlation coefficients
Timing Tumor characteristics Nerve-sparing Hormone 
therapy
Pearson r
p-value
Age at RP Follow-up 
duration
Age at follow-up PSA T-stage Gleason score
UF -0.093
0.075
-0.091
0.080
-0.119
0.023
-0.167
0.001
-0.139
0.008
-0.184
0.001
0.096
0.066
-0.131
0.017
UB -0.049
0.348
-0.079
0.131
-0.076
0.145
-0.142
0.006
-0.163
0.002
-0.156
0.004
0.117
0.025
-0.105
0.055
SF -0.247
< 0.001
-0.214
<0.001
-0.298
<0.001
-0.111
0.033
-0.144
0.006
-0.150
0.006
0.272
<0.001
-0.113
0.039
SB 0.061
0.244
0.240
<0.001
0.144
0.006
0.050
0.338
-0.180
<0.001
-0.033
0.552
0.162
0.002
-0.143
0.009
Significant correlations (p ≤ 0.05) are in bold.
[UF: urinary function; UB: urinary bother; SF: sexual function; SB: sexual bother; RP: radical prostatectomy]Page 4 of 8
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contrary, age at follow-up and pathological stage nega-
tively affected SF on both univariate and multivariate
analysis.
Differences between NS without HT and non-NS or NS 
with HT at interval follow-up
We analyzed differences between patients who underwent
a nerve sparing procedure without HT and non NS or NS
with HT at 4 different follow up intervals. No differences
in UF, UB and SB were noted between Group A and Group
B subjects. As expected, patients treated with bilateral
nerve sparing prostatectomy, without hormone presented
better SF and SB scores in each time point (SF: NS without
HT: 5 yy: 34,61, 6-7 yy: 27,78, 8-9 yy: 12,60, ≥ 10 yy:
15,77. NNS or NS with HT: 5 yy: 17,06, 6-7 yy: 12,97, 8-9
yy: 8,71, ≥ 10 yy: 7,42. SB: NS without HT: 5 yy 78,26, 6-
7 yy: 77,78 yy, 8-9 yy: 83,75, ≥ 10 yy: 91,07. NNS or NS
with HT: 5 yy 64,19, 6-7 yy: 63,86, 8-9 yy: 73,36, ≥ 10 yy:
82,20). Furthermore, subjects who underwent NS-RP
without HT reported significantly higher SF scores 5-7
years postoperatively compared with Group B subjects
[See Figure 1].
The high urinary function and bother scores in the NS
without HT group at follow up 8-9 years (see Figure 1),
can be explained by the low number of patients (20), with
the consequent lack of worse urinary outcomes.
Correlation between symptoms and bother at interval 
follow- up in Group A subjects
For the analysis of correlation between symptoms and
bother at 4 different follow up intervals in Group A sub-
jects, as shown in Figure 2, our subjects reported similar
Table 3: Multivariate analysis of the whole study sample with logistic regression model (forward, stepwise variable entry)
Timing Tumor characteristics Nerve-sparing Hormone 
therapy
r
p-value
Age at RP Follow-up 
duration
Age at follow-up PSA T-stage Gleason score
UF / / -0.609
0.024
-3.557
0.163
-3.103
0.163
-2.878
0.072
/ -5.607
0.056
UB / / / -2.944
0.207
-4.161
0.051
-2.272
0.125
2.774
0.046
-3.718
0.189
SF -1.304
0.617
-0.229
0.302
0.176
0.946
-1.104
0.601
-4.264
0.024
-2.106
0.110
3.783
0.004
-4.259
0.044
SB / 0.290
<0.001
0.272
0.336
/ -4.852
0.018
/ 5.101
<0.001
-7.205
0.076
Significant results (p ≤ 0.05) are in bold.
[UF: urinary function; UB: urinary bother; SF: sexual function; SB: sexual bother; RP: radical prostatectomy. [/: Not included for the multivariate 
analyses]]
Table 4: Univariate and multivariate analyses of subjects treated with nerve-sparing RP without hormone treatment.
Timing Tumor characteristics
r
p-value
Age at RP Follow-up duration Age at follow-up PSA T-stage Gleason score
SF* -0.204
0.050
-0.184
0.077
-0.258
0.012
0.053
0.612
-0.207
0.046
-0.096
0.359
SB* 0.098
0.350
0.161
0.124
0.143
0.170
-0.064
0.543
-0.015
0.889
-0.031
0.771
SF# 1.841
0.303
/ -3.138
0.056
/ -12.530
0.027
/
Significant results (p ≤ 0.05) are in bold.
[SF: sexual function; SB: sexual bother./: Not included for the multivariate analyses]Page 5 of 8
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between UF and UB scores were very similar at each of the
4 follow-up intervals. Increased follow-up duration was
characterized by a progressive deterioration in SF and an
improvement in SB, with the consequent dissociation of
the correlation between SF and SB from 8 to 10 years after
RP.
Discussion
Urinary and sexual outcomes following RP may differ by
age: younger men usually have better preservation of uri-
nary and sexual function after RP, with less bother com-
pared to older men [12]. Higher baseline urinary and
sexual function scores among younger men may drive
their superior age-related outcomes [13]. Furthermore,
urinary and sexual function usually worsens with age [14]:
in a population-based study on long-term prostate cancer
survivors, urinary incontinence and erectile dysfunction
occurred more often among post-prostatectomy patients
compared with the regular population, differences that
cannot be explained merely by age [15]. In our study,
worse UF was most common in older men several years
after surgery. In particular, age at follow-up had the
strongest association with postoperative incontinence, all
other covariates held constant. In addition, after NS-RP
without HT, follow-up age was negatively associated with
erectile function: these older men reported erectile dys-
function independent of age at the time of RP and follow-
up duration. Patients selected for NS-RP who did not
require subsequent HT were essentially cancer-free; age at
follow-up was the foremost determinant for sexual func-
tion. Among the entire cohort, longer disease-free interval
after surgery seems to be associated with reduced sexual
bother independent of patient age. The absence of bio-
chemical failure several years after RP may allow better
tolerance of postoperative erectile dysfunction.
RP in locally advanced prostate cancer (pT3) offers the
potential for cancer control with or without additional
treatment [16]. In a retrospective study on RP performed
in high risk prostate cancer, Catalona reported a preserva-
tion of continence and potency in 92% and 64% of cases
respectively [17]. Furthermore, Zincke confirmed the
good disease-free outcomes in long-term follow-up, and
reported a complication rate in T3 patients similar to that
among patients with T2 Pca [18]. The Department of
Urology of the University of Florence is a centre of excel-
lence for advanced (pT3) prostate cancer [19,20]. This can
explain the high rate of pT3 patients and the low rate of
nerve sparing procedure of the whole population, com-
pared to other centers experience. In our study, we con-
firmed a similar continence rate between low and high
stage PCa patients. Moreover, more advanced stage was
associated with worse sexual outcomes. Among our entire
cohort, this seems to be due to the selection of the major-
ity of these patients for non-NS-RP in those with cT3 Pca.
The negative association between stage and sexual func-
tion among Group A patients (NS-RP without HT) may
relate to more difficult dissection of the neurovascular
bundle from the prostate capsule and the avoidance of an
intrafascial dissection of the periprostatic neurovascular
bundle.
Consistent with analyses of QoL outcomes among RP
patients, the potency rates reported herein after NS-RP
without HT were associated with reduced sexual bother.
The sexual function outcomes among this group were
superior to those undergoing non-NS-RP and NS-RP with
HT up to 7 years after surgery (see figure 1, panel SF).
Beyond 7 years postoperatively, age-related erectile dys-
function may explain the equilibration of sexual function
outcomes between these two patient groups. Moreover,
our population resulted in general less bothered than
other populations such as reported in literature [21]. This
data can be easily explain by the remarkable impact on the
disease free status (PSA < 0.2 ng/mL) at long term follow
up time (> 5 years) of our patients: the conviction of an
effective cancer control allow a better acceptance of sexual
comorbidities.
We found a non-significant trend toward better conti-
nence after NS-RP. Several authors have reported that NS
confers improved postoperative urinary continence
[22,23]. The lack of a correlation in our series may be
related to the advanced age at follow-up and the conse-
quent age-related incontinence of our cohort. Interest-
Mean UF, UB, SF, and SB scores in subjects who underwent NS-RP without HT (Group A - green bars) and no -NS-RP or NS-RP with  subjects (Group B - red bars), stratifi d according to years of follow upFigu e 1
Mean UF, UB, SF, and SB scores in subjects who 
underwent NS-RP without HT (Group A - green 
bars) and non-NS-RP or NS-RP with HT subjects 
(Group B - red bars), stratified according to years of 
follow up. UF: urinary function; UB: urinary bother; SF: sex-
ual function; SB: sexual bother. [* p < 0.05].
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urinary bother compared with men who underwent non-
NS-RP, independent of the degree of urinary inconti-
nence. Urinary bother may correlate more closely with the
severity of storage urinary symptoms, more common after
external beam radiation therapy or brachytherapy, rather
than with the degree of urinary incontinence [24].
Finally, the analyses of Group A men stratified by follow-
up duration demonstrated that, while minimal urinary
symptoms were associated with increased distress related
to those symptoms, the progressive development of erec-
tile dysfunction is well tolerated 8 or more recurrence-free
years after surgery. This confirms that minimal urinary
incontinence continues to be poorly tolerated even after
several years of good cancer control, while erectile dys-
function progressively diminishes as a problem in the
daily life of long-term disease-free survivors.
Our study presents several limitations. First of all, we did
not include some factors that may have biased our out-
comes, such as marital status, education level, employ-
ment status, and income. We were, however, able to
account for factors known to have a substantial influence
on postoperative QoL, such as patient age, pathological
features of the PCa, NS status, and the administration of
hormone therapy. Moreover, all recruited men underwent
RP in centers of excellence by skilled urologists. Thus, our
patient population and QoL outcomes may be not repre-
sentative of the general population. Furthermore, we did
not evaluate generic and general oncological QoL with
validated instruments such as the Medical Outcomes
Study Short Form-12 or the European Organization for
Research and Treatment of Cancer QOL-30. Finally, our
findings have the inherent limitations of a retrospective
study, most prominently a lack of baseline QoL data.
Conclusion
We demonstrated that long-term RP outcomes follow a
distinct QoL trajectory. Older men develop worse urinary
continence independent of age at time of surgery or fol-
low-up duration. Pathological stage was an important
determinant of postoperative QoL outcomes, affecting
both urinary and sexual function. Beyond 8 years after NS-
RP without HT, patients noted substantial sexual dysfunc-
tion, but, surprisingly, they were minimally sexually both-
ered. These results contribute to the clinician's ability to
counsel long-term prostate cancer survivors.
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Comparison of function and bother among Group A subjects at interval follow-upFigure 2
Comparison of function and bother among Group A 
subjects at interval follow-up. The table reports Pearson 
correlation coefficients and p-values assessing the correlation 
between function and bother. Non-significant results (p > 
0.05) are in bold. UF: urinary function; UB: urinary bother; 
SF: sexual function; SB: sexual bother; RP: radical prostatec-
tomy.
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